Tempus AI, Inc.
- Open
- 57.54
- Day high
- 62.36
- Day low
- 57.44
- Prev close
- 57.93
- Volume
- 4.8M
- Mkt cap
- $10.4B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 25.0
- P/S
- 7.6
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$19.8M over the last 3 months (0 open-market buys, 17 sales)
- 🏛Institutions accumulating (13F)
Tempus AI, Inc. (TEM) is a Healthcare company listed on NASDAQ. The stock is down 3% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 17 sales (SEC Form 4).
Tempus AI, Inc. (TEM) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 5 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TEM earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.21 | $-0.13 | +38.1% | $348M | +0.8% |
| Feb 24, 2026 | $-0.04 | $-0.31 | -609.0% | $367M | +1.3% |
| Nov 4, 2025 | $-0.17 | $-0.11 | +36.2% | $334M | +1.7% |
| Aug 8, 2025 | $-0.23 | $-0.22 | +4.3% | $315M | +5.7% |
| Jun 17, 2024 | — | $-0.38 | — | $146M | — |
| Dec 30, 2023 | — | $-0.30 | — | $148M | — |
| Sep 29, 2023 | — | $-0.31 | — | $136M | — |
TEM insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 29, 2026 | Rogers James Williamofficer: Chief Financial Officer | Sell | 11,529 | $55.00 |
| Jun 29, 2026 | Doudna Jennifer Adirector | Sell | 2,673 | $55.00 |
| Jun 3, 2026 | Epstein David Rdirector | Sell | 250 | $49.40 |
| May 29, 2026 | LEFKOFSKY ERIC Pdirector, 10 percent owner, officer: CEO and Chairman | Sell | 24,318 | $46.89 |
| May 29, 2026 | LEFKOFSKY ERIC Pdirector, 10 percent owner, officer: CEO and Chairman | Sell | 35,721 | $46.17 |
| May 29, 2026 | LEFKOFSKY ERIC Pdirector, 10 percent owner, officer: CEO and Chairman | Sell | 97,279 | $46.89 |
| May 29, 2026 | LEFKOFSKY ERIC Pdirector, 10 percent owner, officer: CEO and Chairman | Sell | 8,932 | $46.17 |
| May 26, 2026 | Frederick Wayne A.I.director | Grant | 5,913 | — |
| May 26, 2026 | Epstein David Rdirector | Grant | 5,913 | — |
| May 26, 2026 | Doudna Jennifer Adirector | Grant | 5,913 | — |
| May 26, 2026 | BARRIS PETER Jdirector | Grant | 5,913 | — |
| May 26, 2026 | Belcher Eric Ddirector | Grant | 5,913 | — |
| May 26, 2026 | West Nadjadirector | Grant | 5,913 | — |
| May 26, 2026 | Leonsis Theodoredirector | Grant | 5,913 | — |
| May 26, 2026 | Gottlieb Scottdirector | Grant | 5,913 | — |
Source: TEM SEC Form 4 filings, latest Jun 29, 2026. For informational purposes only — not investment advice.
See the full TEM insider & 13F page →Tempus AI, Inc. company profile
Overview
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company founded in 2015 and headquartered in Chicago, Illinois. The company was originally incorporated as Tempus Labs, Inc. before changing its name to Tempus AI, Inc. in January 2023 to reflect its focus on artificial intelligence applications in healthcare. Tempus operates as a precision medicine platform that combines genomic testing, clinical data analytics, and AI-powered insights to advance cancer care and treatment decisions. The company went public in 2012 and has grown through strategic acquisitions and partnerships to become a significant player in the molecular diagnostics and healthcare data analytics space.
Business
Tempus AI operates in the precision medicine industry, which uses genetic and molecular information to tailor medical treatments to individual patients. The company's core business revolves around genomic sequencing and testing combined with healthcare data analytics powered by artificial intelligence. The company operates two primary business segments. The Genomics segment generates approximately 76% of total revenue and provides comprehensive genomic profiling tests for cancer patients. These tests analyze tumor DNA to identify genetic mutations that can guide treatment decisions - essentially creating a molecular "fingerprint" of each patient's cancer. The segment includes oncology testing for tumor profiling, hereditary cancer screening through their Ambry Genetics acquisition, and emerging Minimal Residual Disease (MRD) testing that detects microscopic amounts of cancer remaining after treatment. The Data and Services segment accounts for approximately 24% of revenue and monetizes Tempus's vast database of linked clinical, molecular, and imaging data. This segment includes Insights, a licensed library of de-identified patient data, and Trials, which provides clinical trial matching services. The company also offers Algos, a suite of AI-powered diagnostic algorithms, and platforms like Hub for test management and Lens for data analysis by researchers. Tempus has built what it claims is the world's largest oncology database, connecting to over 3,000 healthcare institutions. This data foundation enables the company to develop AI models and algorithms that can predict treatment outcomes, identify suitable clinical trials for patients, and provide insights to pharmaceutical companies developing new cancer therapies.
Revenue model
Tempus generates revenue through multiple complementary business models. The Genomics segment operates on a traditional diagnostic testing model, charging healthcare providers, hospitals, and patients for comprehensive genomic profiling tests. Average selling prices range from $1,530 for standard tests to $4,500 for advanced ADLT (Advanced Diagnostic Laboratory Test) status tests. Revenue is primarily generated through insurance reimbursements, though some patients pay out-of-pocket. The Data and Services segment operates on subscription and licensing models. Pharmaceutical and biotechnology companies pay licensing fees to access Tempus's de-identified patient database for drug development research. The company also generates revenue through clinical trial matching services, where pharmaceutical companies pay to identify suitable patients for their studies. Additionally, Tempus offers AI-powered diagnostic algorithms and analytics tools on a subscription basis. Several factors can significantly impact Tempus's margins. Reimbursement rates from insurance companies directly affect profitability, with higher reimbursement for ADLT-status tests providing substantial margin improvements. Test volume growth creates operating leverage as fixed laboratory costs are spread across more tests. Payer mix between commercial insurance, Medicare, and cash-pay patients affects average selling prices. On the cost side, laboratory automation and economies of scale in genomic sequencing reduce per-test costs over time. The company's data business benefits from network effects - as more institutions contribute data, the database becomes more valuable to pharmaceutical customers, enabling premium pricing for data licenses. Competition from other genomic testing companies and potential disruption from new technologies could pressure margins, while regulatory changes affecting reimbursement policies represent ongoing risks to the business model.
Competitive moat
Tempus AI possesses a moderate but growing competitive moat built primarily around its proprietary dataset and network effects. The company's primary competitive advantage lies in its comprehensive oncology database, which contains linked clinical, molecular, and imaging data from over 3,000 healthcare institutions. This dataset becomes more valuable as it grows larger, creating positive feedback loops where more data attracts more pharmaceutical customers, which generates more revenue to fund further data acquisition and AI development. The company benefits from switching costs in both segments. Healthcare providers that integrate Tempus's testing workflows and platforms face operational friction when switching to competitors. Pharmaceutical companies that license Tempus data and develop insights based on it have invested significant resources that would be difficult to replicate with alternative providers. The company's AI algorithms and models trained on this proprietary dataset represent another defensive element, as competitors would need similar data scale to develop comparable capabilities. However, Tempus faces significant competitive threats that limit the strength of its moat. In genomic testing, the company competes with established players like Foundation Medicine (owned by Roche), Guardant Health, and Exact Sciences, all of which have their own proprietary datasets and testing capabilities. The underlying genomic sequencing technology is not proprietary to Tempus, and competitors can potentially replicate testing services. In the data business, large technology companies like Google, Microsoft, and Amazon have substantial AI capabilities and could potentially partner with healthcare systems to create competing datasets. Additionally, regulatory changes could affect data usage rights, and healthcare systems might choose to retain more control over their patient data rather than sharing it with third-party companies. The company's moat is strengthening over time but remains vulnerable to well-funded competitors and technological disruption.
Risks & safety
Tempus AI presents moderate financial risk with improving fundamentals but ongoing cash burn concerns. **Cash and Solvency:** - Cash position of $151.6 million as of Q1 2025, down from $341 million in Q4 2024 - Significant quarterly cash burn of approximately $109 million in free cash flow - Current ratio of 1.71 indicates adequate short-term liquidity - High debt-to-equity ratio of 2.63 raises leverage concerns **Valuation Metrics:** - Trading at 25.2x book value, indicating high valuation expectations - Negative EBITDA of -$68.7 million in Q1 2025, though improving from prior year - Company guidance suggests path to EBITDA positive in 2025 - Revenue growing at 75% year-over-year provides growth justification for premium valuation **Other Considerations:** - Strong revenue growth trajectory with guidance of $1.25 billion for 2025 - Recent $200 million AstraZeneca partnership provides cash flow visibility - Acquisition of Ambry Genetics for $600 million adds debt but strengthens market position - Dependence on reimbursement rates creates regulatory risk to cash flows
Recent development
Over the past few years, Tempus AI has executed several strategic initiatives to strengthen its market position and accelerate growth. The company's most significant move was the $600 million acquisition of Ambry Genetics in early 2025, which added hereditary cancer screening capabilities and is expected to contribute high-teens growth rates. This acquisition complements Tempus's existing oncology testing portfolio and provides access to Ambry's established payer relationships and customer base. In the data and AI segment, Tempus secured a landmark $200 million, three-year licensing agreement with AstraZeneca and Pathos to build what the company describes as the world's largest foundation model in oncology. This partnership validates Tempus's data assets and provides significant cash flow visibility. The company has also expanded its AI applications, launching Olivia AI, a personal health concierge app that operates on a subscription model at $12 per month. Tempus has made substantial investments in its Minimal Residual Disease (MRD) testing capabilities, which detect microscopic amounts of cancer remaining after treatment. While currently limited by reimbursement challenges, management expects this to become a significant growth driver as payer coverage expands in late 2025. The company has also focused on achieving ADLT (Advanced Diagnostic Laboratory Test) status for its comprehensive genomic profiling tests, which would increase reimbursement rates from approximately $1,530 to $4,500 per test. Strategic partnerships have been a key focus, with Tempus extending its five-year agreement with Google for cloud computing and AI development, and becoming an in-network provider for Blue Cross Blue Shield plans to improve reimbursement rates. The company has also expanded its data connectivity, acquiring Deep 6 to enhance its provider platform and data integration capabilities. These developments position Tempus for its stated goal of achieving EBITDA profitability in 2025 while maintaining strong revenue growth rates.
TEM company profile · for informational purposes only — not investment advice.
Track TEM with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free